Kengo Nagashima

Tokyo, 1608582, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 198 publications

Study of weight loss intervention to find an effective strategy for obesity management and the TARGET of weight loss amount for reducing health disorders (SLIM-TARGET): a randomized controlled trial.

Study of weight loss intervention to find an effective strategy for obesity management and the TARGET of weight loss amount for reducing health disorders (SLIM-TARGET): a randomized controlled trial.

Journal: Endocrine journal

Published: September 02, 2026

Response to Zhang and Lu.

Response to Zhang and Lu.

Journal: Journal of the National Cancer Institute

Published: May 14, 2026

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1.

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1.

Journal: British journal of cancer

Published: March 14, 2026

A Pancreatic Ductal Adenocarcinoma Diagnostic System Using Serum Extracellular Vesicle Detection with Optimized Lectin Combination Using Machine Learning.

A Pancreatic Ductal Adenocarcinoma Diagnostic System Using Serum Extracellular Vesicle Detection with Optimized Lectin Combination Using Machine Learning.

Journal: Cancers

Published: February 07, 2026

Consultation rates, comorbidities, and prescriptions for menopausal disorders among Japanese working women: a descriptive study using a nationwide administrative insurance claims database.

Consultation rates, comorbidities, and prescriptions for menopausal disorders among Japanese working women: a descriptive study using a nationwide administrative insurance claims database.

Journal: Maturitas

Published: January 07, 2026

Association of the PD-L1 CPS With the Efficacy of First-Line Nivolumab Plus Chemotherapy for Unresectable Advanced or Recurrent Gastric Cancer.

Association of the PD-L1 CPS With the Efficacy of First-Line Nivolumab Plus Chemotherapy for Unresectable Advanced or Recurrent Gastric Cancer.

Journal: Cancer medicine

Published: December 24, 2025

Survival after pathological complete response following neoadjuvant chemotherapy versus chemoradiotherapy for oesophageal squamous cell carcinoma.

Survival after pathological complete response following neoadjuvant chemotherapy versus chemoradiotherapy for oesophageal squamous cell carcinoma.

Journal: The British journal of surgery

Published: December 23, 2025

ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer.

ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer.

Journal: Cancer research communications

Published: December 17, 2025

Japanese nationwide survey to track the impact of long COVID over 3 years.

Japanese nationwide survey to track the impact of long COVID over 3 years.

Journal: Environmental health and preventive medicine

Published: October 29, 2025

Association between modifiable lifestyle factors and the incidences of sudden sensorineural hearing loss and Meniere's disease: A population-based nested case-control study.

Association between modifiable lifestyle factors and the incidences of sudden sensorineural hearing loss and Meniere's disease: A population-based nested case-control study.

Journal: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Published: October 19, 2025

Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials.

Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials.

Journal: Journal of the National Cancer Institute

Published: October 08, 2025

Nivolumab with definitive chemoradiotherapy for oesophageal squamous cell carcinoma (NOBEL): a multicentre, single-arm, phase 2 feasibility trial.

Nivolumab with definitive chemoradiotherapy for oesophageal squamous cell carcinoma (NOBEL): a multicentre, single-arm, phase 2 feasibility trial.

Journal: EClinicalMedicine

Published: August 27, 2025

Showing 1-12 of 198

Last Updated: 09/26/2026